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Background: Co-infections of HBV and HIV are frequent due to similar routes of transmission. In that transmission
through blood is an important route for both HBV and HIV, evaluation of the prevalence of HBV in HIV infected blood
donors may be important for transfusion safety. In addition, because the epidemiological characteristics of HBV in HIV
infected patients and blood donors may differ from each other, understanding of it could be significant for therapy
and prevention of HBV in HIV infected adults. However, data reported on these in Chinese people remains limited.
Methods: 614 HIV confirmed positive samples were collected from blood donors and patients and were screened for
HBsAg and HBV DNA. The samples screened reactive for HBsAg or positive for HBV DNA were tested for the other
serological markers of HBV including anti-HBs, HBeAg, anti-HBe and anti-HBc. For the samples tested positive for HBV
DNA, the S region of HBV was amplified by nested PCR and the HBV genotypes were determined.
Results: HBV coinfections were found in 12.9% (79/614) HIV infected individuals including 42/417(10.1%) blood donors
and 37/197 (18.8%) AIDS patients. In the HBsAg positive individuals, 80.0% were HBeAg negative in which 10.0% were
HBV DNA negative and 38.3% with HBV DNA lower than 2000 IU/ml. The average HBV DNA levels were lower in donors
than in patients. In the HBV DNA positive populations, HBV genotypes B, A and C accounted for 48.1%, 22.8% and 8.86%
respectively. Mutations related to the failure of HBsAg detection were found in 2 of the 4 HBsAg-/HBV DNA + subjects.
Conclusions: High prevalence of HBV in HIV infected individuals was found in this study. Hence, we recommend routine
testing of HBV for patients newly diagnosed with HIV/AIDS in China. Some HIV-HBV co-infected patients remain
undiagnosed if only conventional serological markers for HBV are used and it’s important to detect HBV DNA for HIV
infected patients. HBV DNA levels were relatively low in HBeAg negative patients, thus this serologic marker may be
useful in prioritizing patients on their need for HBV treatment in settings in which HBV DNA is not available.
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Hepatitis B virus (HBV) and human immunodeficiency
virus (HIV) are both major public health problems
worldwide. They share similar routes of transmission,
namely through blood and blood products, sharing of
needles to inject drugs, and sexual activity, resulting in* Correspondence: messa1022@126.com; 108349730@qq.com
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Studies reported that coinfection with HBV was a well-
documented cause of liver-related complications in in-
dividuals with HIV infection and is associated with an
increased risk of mortality [2-4]. Because of the significant
burden and clinical impact of HBV in HIV-infected indi-
viduals, understanding the epidemiologic characteristics
of HBV infection in HIV-infected populations is crucial.
It has been estimated that HBV accounts for 400 million
chronic infections worldwide. The prevalence of HBV
infection among HIV-infected persons varies markedly,
from 5% to 30% in different regions of the world [5].
HBV infection is highly endemic in China, with 5.84%This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tion of 1–59 years of age in 2007 [6]. However, data on
the prevalence of HBV coinfection in HIV infected adults
in China remains limited [7,8].
HBV has ten genotypes (A through J) with wide geo-
graphic distribution. Genotypes B and C are most com-
mon in Asia, and genotype A, which is more responsive
to interferon therapy than are the other genotypes, is most
common in Northern and Central Europe [9]. However,
the role of HBV genotypes in the natural history of the
infection and in the response to therapy in patients with
HIV coinfection is unclear. In China, the most common
genotypes of HBV in individuals who have HBV infection
alone are C and B [10]. However, data on the HBV
genotype distribution in HIV/HBV co-infected Chinese
individuals still remains limited.
Because of the different clinical characteristics of HIV
infected patients and blood donors, the epidemiological
characteristics of HBV in the two HIV infected groups
may differ from each other, which could be significant for
therapy and prevention of HBV in HIV infected adults.
Sichuan is a southwest province in China with a total
population of about 89 million. The prevalence of HIV
in Sichuan is higher than that in many other provinces
and ranks in the top five provinces of highest prevalence
in China. Therefore, in this study we investigated the
prevalence of HBV in newly diagnosed HIV-infected
blood donors and AIDS patients in Sichuan, China and
analyzed the HBV genotype distribution, viral loads,
serological markers of HBV and their relationships.
Methods
Samples
614 HIV-positive samples were collected between 1995
and 2010 which were screened reactive for anti-HIV1/2
by ELISA(enzyme-linked-immunosorbent serologic assay)
and then confirmed by western blotting using an HIV 1/2
antibody immunoblot kit (AUSIA, Hangzhou, China) at
the HIV Confirmation Laboratory of the Institute of Blood
Transfusion, Chinese Academy of Medical Science. The
approval from the Ethical Committee of Chinese Academy
of Medical Science was gained for the use of these samples
for research purposes. All samples collected in different
years were from different individuals. Of all the 614 sero-
logically HIV-positive participants, 417 were blood donors
(348 male, 69 female) and 197 were clinical patients from
hospitals in the province of Sichuan, China (152 male, 45
female) (Table 1). The mean age of these individuals was
34.6 ± 12.3 years (range, 15–79 years). There were 453
(81.4%) men with a mean age of 34.9 ± 12.5 years (range,
15–79 years) and 120 (18.6%) women with a mean age of
33.8 ± 11.7 years (range, 18–67 years). In China, all the
blood donors should be screened for anti-HIV by ELISA
and the donors screened reactive will be excluded bydonation. Thus, all the 417 blood donors were excluded
by donation. HBV coinfection was defined as positive
for HBsAg or HBV DNA. All the donors and patients
were newly diagnosed HIV infected and therapy-naïve
individuals.Serological tests
All the samples were screened for Hepatitis B surface anti-
gen (HBsAg) using ELISA Kits (Kehua Biotechnology,
Shanghai, China) according to the manufacturer’s in-
structions. This kit has not yet been evaluated for per-
formance on HBsAg mutant panels. Confirmatory test
(Livzon Diagnostics INC., Zhuhai, China) was conducted
on the samples tested reactive for HBsAg by ELISA. For
the samples confirmed positive for HBsAg, other four
serological markers of HBV were tested including antibody
to Hepatitis B surface antigen (anti-HBs), Hepatitis B e
antigen (HBeAg), antibody to e antigen (anti-HBe) and
antibody to Hepatitis B core antigen (anti-HBc). Accord-
ing to the instructions, the sensitivity of the assay for
HBsAg was 0.05 ng/mL.Viral DNA extraction and amplification of the S region
Aliquots of plasma (50 μL) from four HIV-positive blood
samples were pooled and subjected to nucleic acid extrac-
tion using QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions
and 50 μL of eluted DNA was stored at −70°C until use.
The HBV S region was amplified by nested PCR using a
thermal cycler (Veriti, Applied Biosystems) with BS1
(nt 203–221, 5′-GCGGGGTTTTTCTTGTTGA-3′) as
the sense primer and BS2 (nt 788–769, 5′-GGGACTC
AAGATGTTGTACAG-3′) and BS3 (nt 712–731, 5′-A
AGCCCTACGAACCACTGAA-3′) as the antisense primers
for the first-round and second-round PCR, respectively.
The first-round PCR was performed with Taq DNA
polymerase (Tiangen) in a total volume of 40 μL, with
the following reaction variables: predenaturation at 95°C
for 5 minutes, followed by 35 cycles of 15 seconds of de-
naturation (95°C), 30 seconds of annealing (53°C), and
30 seconds of extension (72°C), with a final extension at
72°C for 5 minutes. The cycling conditions of the
second-round PCR were the same as the first-round
PCR but using 2 μL of the first-round PCR product as
template [11]. After nested-PCR, 200 μL of plasma from
each sample of HBV DNA positive pools underwent nu-
cleic acid extraction independently using the same
protocol as mentioned above and then nested PCR of S
region were performed for every extracted DNA. To
avoid false positive results, comprehensive procedures
were followed to prevent sample cross-contamination,
and test results were accepted as valid only when obtained
in duplicate.
Table 1 Characteristics and HBV coinfection prevalence of HIV infected individuals
Total (%) HBV positive (%) Donors Patients P
(N = 614) (N = 79) Total HBV positive % Total HBV positive % Donors
VS patients(N = 417) (N = 42) (N = 197) (N = 37)
Total 614 79 (12.9) 417 42 10.1 197 37 18.8 0.003
Gender
Male 500 (81.4) 66 (13.3) 348 36 10.3 152 30 19.7 0.004
Female 114 (18.6) 13 (11.4) 69 6 8.7 45 7 15.6 0.26
Age
≤35y 356 (58.0) 46 (12.9) 281 30 8.7 75 16 21.3 0.01
36-45y 127 (20.7) 15 (11.8) 98 8 7.1 29 7 24.1 0.02
>45y 80 (13.0) 8 (10.0) 33 4 11.1 47 4 9.8 0.6
unknown 51 (8.3) 10 (19.6) 5 0 0 46 10 21.7
Year
1995-2007 120 (19.5) 16 (13.3) 86 9 10.5 34 7 20.6 0.14
2008 161 (26.2) 22 (13.7) 128 14 10.9 33 8 24.2 0.047
2009 155 (25.2) 21 (13.5) 94 9 9.6 61 12 19.7 0.07
2010 178 (29.0) 20 (11.2) 109 10 9.2 69 10 14.5 0.27
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The PCR products were analyzed by electrophoresis in
1.5% agarose gels and purified using a commercially
available kit (NucleoSpin Extract II kit, Macherey-Nagel
GmbH & Co. KG, Du¨ren, Germany) according to the
manufacturer’s instructions. Purified products were used
as templates in cycle sequencing reactions. Nucleotide
sequences were determined from both strands using
primers BS1 and BS3, and the resulting sequences were
read directly with a genetic analyzer (ABI 3730, Applied
Biosystems). For the single sequence with no heterogeneous
sites, the HBV genotypes were determined by phylogenetic
analysis with a panel of reference sequences from genotypes
A to H retrieved from GenBank as reported [11]. If the
amplified sequence had heterogeneous sites identified by
sequencing both strands, multiplex PCR was used for
genotyping as reported previously [11].Quantitative assay of HBV-DNA
HBV-DNA level of the HBV infected samples, HBsAg
positive or HBV DNA detected by nested-PCR, was tested
by real-time fluorescence quantitative PCR with TaqMan
probe using the Quantitative Hepatitis B Virus PCR Fluoro-
gence Diagnostic Kit (PG Biotechnology, Shenzhen, China)
[12]. Standard curves of the reactions were constructed
using quantitation standard supplied by manufacturer.
The detection limits of this method range from 5 × 102 to
5 × 107 IU/ml using a serum sample volume of 100 ul.
The quantitative HBV DNA testing was performed three
times on all samples and the average was recorded as the
result for the sample.Analysis of mutations in the S region
The presence of amino acid mutations in the antigenic
loop was analyzed from amino acid 103 to 173 of
HBsAg and compared to a consensus sequence from the
same genotype. Mutations related to genetic polymorphisms
were noted, but the focus was placed on mutations
reported to be associated with diagnostic failure [13].
Statistical analysis
Quantitative data were expressed as mean ± SD and the
viral load was expressed as logarithmic transformation
of original values. Comparisons between groups were
analyzed by chi-square test or Fisher’s exact test for
categorical variables and by Student’s t-test for quanti-
tative variables. P-values below 0.05 were considered
significant. All statistical analysis was performed using
SPSS software for Windows 16.0 (SPSS, Chicago, IL).
Results
The prevalence of HBV in HIV infected donors and
AIDS patients
Of the 614 HIV infected individuals investigated, 79
(12.9%) were found to have HBV coinfection, including
42 blood donors with mean age of 32.6 ± 8.8 years old
and 37 AIDS patients with mean age of 35.1 ± 12.7 years
old. The prevalence of HBV coinfection in HIV infected
blood donors (42/417, 10.1%) was found significantly
lower than that in AIDS patients (37/197, 18.8%, P = 0.003).
Of the 79 subjects, 69 were positive for both HBV DNA
and HBsAg. There were 6 subjects detected positive for
HBsAg but negative for HBV DNA and 4 subjects detected
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in Table 1, the prevalence of HBV coinfection in different
gender group, different age group and different year group
of samples collected was analyzed and no significant differ-
ence was found.
Serological markers of HBV and the HBV DNA levels
As shown in Table 2, of the 75 HBsAg positive subjects,
39 were from HIV infected donors and 36 were from
AIDS patients and the average HBV DNA level of the
former group was significantly lower than that of the
latter group (4.2 ± 1.1 LogIU/ml VS 5.0 ± 1.7LogIU/ml,
P = 0.008). Of all the HBsAg positive subjects, 15
(20.0%) were found HBeAg positive and 60 (80.0%)
were found HBeAg negative. The rate of HBeAg positivity
of HBsAg positive donors (3/39, 7.7%) was significantly
lower than that of HBsAg positive patients (12/36, 33.3%,
P = 0.01) while the rate of HBeAg negativity of HBsAg
positive donors (36/39, 92.3%) was significantly higher
than that of HBsAg positive patients (24/36, 66.7%, P =
0.01). In the 60 HBsAg +HBeAg- subjects, 6 (10.0%) were
HBV DNA negative and 23 (38.3%) with HBV DNA less
than 2000 IU/ml. The average HBV DNA level of HBeAg
negative subjects was found significantly lower than
HBeAg positive subjects (P < 0.001) (Figure 1). The rate of
anti-HBc positivity in HBsAg positive donors (28/39,
71.8%) was significantly lower than that in HBsAg positive
patients (34/36, 94.4%, P = 0.009). As shown in Table 3,
of the 13 HBsAg carriers negative for anti-HBc, 11 wereTable 2 Serological markers of HBV and the HBV DNA levels




HBsAg+ ,HBeAg+ 15 20.0(15/75)
Donors 3 7.7(3/39)
Patients 12 33.3(12/36)
HBsAg+ ,HBeAg- 60 80.0(60/75)
Donors 36 92.3(36/39)
Patients 24 66.7(24/36)
HBsAg+ ,anti-HBe+ 19 25.3(19/75)
Donors 7 17.9(7/39)
Patients 12 33.3(12/36)





Patients 2 5.56(2/36)negative for both HBeAg and anti-HBe and 2 were
HBeAg positive. 11 of the 13 samples tested positive
for HBV DNA. All the HBsAg reactivity was confirmed
by neutralization test.
HBV genotypes in the HIV infected donors and AIDS patients
A total of 67 (91.8%) of the 73 HBV DNA positive samples
were successfully genotyped, of which 18 (22.8%, 95%CI:
13.5%-32.0%) were found infected with genotype A HBV,
38 (48.1%, 95%CI: 37.1%-59.1%) with genotype B, 7
(8.86%, 95%CI: 2.59%-15.1%) with genotype C, 3 (3.80%,
95%CI: 0.42%-8.01%) with genotype D, 1 (1.27%, 95%CI:
0.20%-3.73%)with mixture of genotype B and D and no
subjects with genotypes E to H. No significant difference
was found in the genotypes distribution of the two groups.
The average HBV DNA level of the subjects infected with
genotype A HBV was 4.0 ± 0.5 Log IU/mL which was
significantly lower than that of the subjects infected with
genotype B (4.7 ± 1.5 Log IU/mL, P = 0.004) and genotype
C HBV (6.4 ± 1.8 Log IU/mL, P = 0.005, Figure 2). In
addition, the average HBV DNA level of the subjects
infected with genotype B HBV was found significantly
lower than that of the subjects infected with genotype C
HBV (P = 0.02, Figure 2).
The characteristics of the HBsAg negative HIV/HBV
coinfection subjects
Of the 79 HBV infected subjects, 4 (0.65%, 4/614) were




P (HBV DNA level of
donors VS patients)
4.6 ± 1.5
4.2 ± 1.1 0.008
5.0 ± 1.7
6.9 ± 1.0
0.01 6.6 ± 0.5 0.24
6.9 ± 1.1
4.1 ± 0.9
0.01 4.1 ± 0.9 0.75
4.1 ± 0.9
4.3 ± 1.4
0.13 3.9 ± 0.7 0.12
4.6 ± 1.6
4.7 ± 1.5
0.009 4.7 ± 1.3 0.41
4.8 ± 1.6
4.3 ± 1.4
0.009 3.7 ± 0.6 0.006
6.6 ± 1.5
Figure 1 The average HBV DNA levels in different serological markers groups. The average HBV DNA level of HBeAg positive subjects was
found significantly higher than anti-HBe positive subjects, HBeAg negative subjects, anti-HBc positive subjects and anti-HBc negative subjects (P < 0.001).
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subjects was listed in Table 4. All the four subjects were
younger than 40 years old with one female (number 1)
and 3 males (number 2 to 4). For number1, the HBV
DNA level was 1.44 × 105 which was higher than the
viral load of number 2 to 4. The HBeAg and anti-HBe
were tested positive for number 1 while negative for all
the other three males. All the four subjects were tested
positive for anti-HBc. The subject of number 1 was found
infected with genotype C HBV while number 3 and 4
infected with genotype B HBV and number 2 infected
with HBV of undetermined genotype. In addition, the
sequence analysis showed that mutations of P127S andTable 3 The information of the HBsAg+/anti-HBc- subjects*
Samples Gender Age Source
1 Female 39 Patient
2 Female 41 Donor
3 Female 31 Donor
4 Female 49 Donor
5 Female 26 Donor
6 Male 25 Patient
7 Male 54 Donor
8 Male 24 Donor
9 Male 25 Donor
10 Male 27 Donor
11 Male 30 Donor
12 Male 34 Donor
13 Male 18 Donor
P: positive; N: negative.
*:All the samples were confirmed by neutralization.G145R occurred in the HBV infected by number 1 subject
and mutation of L109M occurred in number 3 infected
HBV while no mutation was found in the HBV infected
by number 2 and 4.
Discussion
Coinfection of HBV with HIV complicates the clinical
course, management and may also adversely affect
therapy for HIV infection. Treatment of patients with
HIV/AIDS coinfected with HBV is even more complex
[14,15]. Thus it is important to determine whether patients
with HIV/AIDS are coinfected with HBV. All over the
world, increasing attention has focused on HIV coinfectionAnti-HBs HBeAg Anti-HBe HBV DNA
N P N P
N N N P
P N N P
N N N P
N N N P
N P N P
N N N P
P N N N
P N N P
P N N P
P N N P
P N N N
N N N P
Figure 2 The average HBV DNA levels of different HBV genotype groups. The average HBV DNA level of the subjects infected with
genotype A HBV was significantly lower than that of the subjects infected with genotype B (P = 0.004) and genotype C HBV (P = 0.005).
The average HBV DNA level of the subjects infected with genotype B HBV was found significantly lower than that of the subjects infected
with genotype C HBV (P = 0.02).
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reported the HIV/HBV prevalence in China [7,8]. How-
ever, most of the studies just adopted seroepidemiologi-
cal survey methods to detect HBsAg to initially assess
the status of HBV infections in HIV/AIDS populations in
China, which may underestimate the actual prevalence of
HBV for many reasons including window period infection,
HBsAg detecting negative for mutations in S region and
occult HBV infection. In this study we conducted both
HBsAg and HBV DNA detection to assess the HBV preva-
lence in HIV infected populations and got a result of
12.9% which was higher than the HBV prevalence in the
Chinese general population [6]. In addition, the data we
got suggests higher HIV/HBV prevalence in Chinese pop-
ulations than reported by other studies [7,8]. One reason
may be that HBV DNA detection was conducted and
some HBsAg negative HBV DNA positive subjects were
found in this study. In addition, HBV and HIV sole preva-
lence in the general population in different regions may
affect the prevalence of HIV/HBV coinfection determinedTable 4 The information of the HBsAg-/HBV DNA + subjects*
Samples Gender Age Source Collection year HBV DNA Level (IU/
1 Female 21 Donor 2008 1.44 × 105
2 Male 35 Donor 2009 <500
3 Male 23 Donor 2010 1.08 × 103
4 Male 38 Patient 2007 3.35 × 103
ID: indeterminate; P: positive; N: negative.
*:All the four subjects were positive for anti-HBc.in different researches and both HBV and HIV are more
endemic in Sichuan, the region we studied, than many
other provinces in China. The HBV/HIV coinfection
prevalence of 12.9% in the present study is significant
and confirms that HBV is a major threat to HIV infected
individuals in China, as reported in other parts of the
world [5]. In our study, the HBV coinfection prevalence
was determined separately in HIV infected blood donors
and AIDS patients and the result showed that the HBV
prevalence in the former group was significantly lower
than that in the latter group, which may be due to that
the HBV prevalence in Chinese blood donors was lower
than that in the general Chinese people.
In this study, more HBeAg negative individuals were
found in the HBsAg positive donors than in the patients
and the average HBV DNA levels were determined lower
in donors than in patients, which may explain why most
of the HBV/HIV infected blood donors are asymptomatic.
In addition, in this study, 10% of the HBeAg-negative pat-
ents had an undetectable HBV DNA, and an additionalml) HBV Genotype HBeAg anti-HBe anti-HBs Mutations
C P P N P127S and G145R
ID N N N NO
B N N P L109M
B N N N NO
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is the level above which treatment for HBV infection is
considered. In contrast, all of the HBeAg-positive subjects
had detectable HBV DNA levels that were more than
105 IU/ml. In the Nigerian study, these low levels were
also found primarily in HBeAg-negative patients and these
findings are supported by the multivariable analysis by
other studies demonstrating that HBeAg-positive status
was the only factor associated with higher HBV DNA levels
[16]. Thus, it is possible to detect HBeAg to determine
if HBV treatment needs to be started in HIV infected
individuals when HBV DNA assays are not available in
resource-limited settings.
Genotypes C and B were the major HBV genotypes
endemic in Mainland China in the individuals with HBV
infection alone and genotype C is more prevalent than
genotype B in general populations in Sichuan province
[10]. In this study, we found the most prevalent genotype
was B and followed by genotype A and C in the HBV/HIV
coinfected individuals, which was quite different from
the genotype distribution in the population with HBV
infection alone. This may explain the high rate of HBeAg
negative individuals in the HBV/HIV coinfected popula-
tions detected in this study in that genotype B HBV is less
virulent than genotype C and genotype B has a higher rate
of seroconversion from HBeAg to anti-HBe. If the HBV
genotype distribution demonstrated in our study is the
fact, it’s good news for HBV/HIV coinfected populations.
However, there is still one question. It is known that HIV
infection would impair the cell mediated responses and
enhances the kinetics of HBV replication, thus, genotype C
HBV, which has greater capability to replicate, is considered
to be more likely to infect the HIV infected individuals.
This seems to be contradictive with HBV genotype distri-
bution determined in our study. Thus, more studies are
needed to determine the HBV genotype distribution in the
HBV/HIV coinfected individuals and its mechanism needs
to be analyzed in the future.
Through HBV DNA detection, 6 HBsAg positive but
HBV DNA negative subjects were found in our study. It
seems to be very rare to find HBsAg in the absence of
HBV DNA which may be due to high sensitivity of HBV
DNA test by nested-PCR used in this study. However,
the existence of HBsAg+/HBV DNA- samples suggested
that the HBV DNA testing can’t substitute the testing of
HBsAg in blood donation screening. In addition, 4 HBV
DNA positive but HBsAg negative subjects were found.
A number of explanations for the positivity of HBV DNA
in HBsAg negative samples have been proposed, including
window period infection, occult HBV infection (OBI),
genetic variations in the S gene and the presence of im-
mune complexes in which HBsAg may be hidden [17].
To analyze the cause of HBsAg negative, we analyzed
the sequence of S gene of the four samples and foundthree mutations in two subjects. All of the three mutations
were located in the sequence coding the central major
hydrophilic region (MHR) from residues 103–173 which
was exposed at the surface of viral particles and may be
related to the failure of HBsAg detection. In the 4 sub-
jects, subject 1 was found with G145R mutation, which
was reported as the most important and best-documented
mutation in MHR and was reported as the most critical
substitution to prevent HBsAg detection. In addition,
subject 1 was found positive for HBeAg and with high
viral load. Thus, Sample 1, very much likely, was a failure
in HBsAg detection due to the outdated quality of the
method used, which manufacturer has not yet taken care
to assess its performance for detecting HBsAg mutants.
It’s perfectly known at present that appropriate modifica-
tions in assay design improve such performance if imple-
mented, including a significant improvement of the ability
to detect samples containing G145R mutants [18,19].
Therefore, the methods used for testing HBsAg should
be carefully selected for avoiding such diagnostic mistakes.
Occult HBV infection (OBI) is characterized by positive
HBV-DNA in serum (and/or hepatic tissues) of individuals
negative for serum HBsAg. A study in Germany showed
that the occult HBV infection rate in patients with
HIV/AIDS was 2.9% [20]. Although occult hepatitis B
infection alone may not have clinical consequences, it
may become injurious when the virus is reactivated after
immunosuppression, which suggests that HIV coinfection
is a high risk for OBI [21,22]. According to the serological
markers testing results and HBV DNA load, subject 3 can
be determined as OBI. Subjects 2 and 4 were detected
positive for only anti-HBc but not for the other four sero-
logical markers. Thus, it’s difficult to determine them as
OBI unless anti-HBc IgM testing would be done to
exclude that they were during the seroconversion phase of
the acute HBV infection.
The current study had some limitations. Firstly, the
sample size was relatively small and it was a single time
point testing without any follow-up. Secondly, Since it
was a cross-sectional study, liver disease characteristics
such as alanine aminotransferase (ALT)/aspartate amino-
transferase (AST) levels and HIV disease characteristics
including CD4+ T-cell counts and HIV RNA levels were
not determined in this study and we could not comment
on the clinical significance of HBV in HIV infected popu-
lations included in our study. Thirdly, the data of HIV
acquired route of the subjects were not collected, thus it’s
impossible for us to analyze the impact of HIV transmis-
sion mode on HBV coinfection. Lastly, a control group of
HIV negative was not included in the study and we could
not compare the HBV infection in the HIV positive group
with the negative group. However, some data about the
HBV infection in general Chinese people were used to do
the comparison.
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The identification of a high prevalence of HBV in HIV
infected individuals in this study indicates the significance
of screening for HBV among patients newly diagnosed
with HIV/AIDS. Hence, we strongly recommend that rou-
tine testing for patients newly diagnosed with HIV/AIDS
should include tests for HBV in China and that treatment
of HBV should become an important part of HIV care.
The hepatitis B infection with negative HBsAg in HIV in-
fected Chinese individuals found in this study suggested
that HIV/HBV coinfected patients remain undiagnosed, if
only conventional serological markers for HBV are used
and it’s important to detect HBV DNA for HIV infected
patients. Reagents with the ability to detect samples
containing mutants should be selected for HBsAg testing
to avoid diagnostic mistakes resulting from mutations in
MHR region. HBV DNA levels were relatively low in
HBeAg negative patients, thus this serologic marker may
be useful in prioritizing patients on their need for HBV
treatment in settings in which HBV DNA is not available.
More studies are needed to determine the HBV genotype
distribution in the HBV/HIV coinfected individuals further.
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